Zumutor Biologics Inc.

Zumutor Biologics Inc. is a US-based biotechnology firm focused on developing innovative NK cell therapeutics to enhance innate immunity and target tumors effectively. Founded in 2013 and headquartered in Cambridge, Massachusetts, Zumutor Biologics specializes in NK cell therapeutics. Kavitha Rodrigues, the CEO and founder, has directed the company's focus toward proprietary therapeutic advancements.

The firm raised USD 6. 2 million in a SERIES A funding round on December 9, 2021, with investors including Siana Capital, Accel, and Bharat Innovation Fund, culminating in a total fundraising of USD 6. 2 million. Zumutor Biologics specializes in developing targeted NK cell therapeutics, utilizing its Human Antibody platform, INABLR®.

The lead product, the Anti-LLT1 monoclonal antibody, targets LLT1 for treating malignancies such as prostate cancer, B-cell lymphoma, and glioblastoma. The company operates R&D facilities in Cambridge, Massachusetts, and Bangalore, India, aiming to enhance patient outcomes through targeted therapies in oncology and immune-mediated diseases. Zumutor Biologics generates revenue primarily through partnerships and collaborations with healthcare institutions and pharmaceutical companies, utilizing licensing agreements and service contracts for clinical testing of its monoclonal antibodies. Financial specifics regarding individual products have not been disclosed, yet the Anti-LLT1 mAb is expected to significantly impact future revenue as it advances in clinical trials.

With the recent SERIES A funding of USD 6. 2 million raised in December 2021, Zumutor Biologics plans to expand its global business operations. The funding will support the development of upcoming products and enhance its market presence, particularly targeting North America and Asia for growth initiatives.